HC Wainwright Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) had its price target hoisted by research analysts at HC Wainwright from $27.00 to $34.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 54.13% from the stock's previous close.

A number of other brokerages also recently commented on VRDN. Oppenheimer restated an "outperform" rating and issued a $28.00 target price (down from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. Wedbush reissued an "outperform" rating and set a $42.00 target price on shares of Viridian Therapeutics in a report on Monday, July 29th. BTIG Research upped their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, September 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Wednesday. Finally, The Goldman Sachs Group lifted their price objective on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday, September 12th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $36.50.

Viridian Therapeutics Stock Down 1.9 %

NASDAQ:VRDN traded down $0.42 during mid-day trading on Thursday, reaching $22.06. The stock had a trading volume of 782,782 shares, compared to its average volume of 1,113,758. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -5.22 and a beta of 1.10. Viridian Therapeutics has a 1-year low of $11.40 and a 1-year high of $27.20. The stock's 50 day simple moving average is $22.35 and its two-hundred day simple moving average is $16.89. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.82 and a quick ratio of 15.82.

Insider Buying and Selling

In other Viridian Therapeutics news, COO Thomas W. Beetham acquired 5,000 shares of the firm's stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the acquisition, the chief operating officer now owns 6,000 shares of the company's stock, valued at approximately $140,460. This trade represents a 500.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, COO Thomas W. Beetham bought 5,000 shares of the business's stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $23.41 per share, with a total value of $117,050.00. Following the transaction, the chief operating officer now directly owns 6,000 shares in the company, valued at approximately $140,460. The trade was a 500.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Stephen F. Mahoney bought 21,400 shares of the business's stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $23.33 per share, with a total value of $499,262.00. Following the transaction, the chief executive officer now owns 21,400 shares in the company, valued at approximately $499,262. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 1,626,400 shares of company stock worth $30,616,312. Corporate insiders own 0.65% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Quest Partners LLC raised its position in shares of Viridian Therapeutics by 344.0% during the second quarter. Quest Partners LLC now owns 6,056 shares of the company's stock valued at $79,000 after buying an additional 4,692 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company's stock worth $87,000 after purchasing an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock worth $156,000 after purchasing an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC raised its position in Viridian Therapeutics by 108.3% in the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company's stock worth $163,000 after purchasing an additional 6,500 shares in the last quarter. Finally, Arizona State Retirement System raised its position in Viridian Therapeutics by 14.7% in the second quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock worth $171,000 after purchasing an additional 1,688 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.